BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months

Depression (MDD) clinical trials and catalysts

Active industry-sponsored trials on ClinicalTrials.gov for major depressive disorder: 92 (65 sponsors; 20 newly posted in the last 180 days, 11 stopped in the last 180 days; 12 new-entrant sponsors). Momentum score 14.7, rank 44 of 91 on the disease-area ranking. As of 2026-11-18.

Phase distribution: Early Phase 1 0, Phase 1 3, Phase 2 23, Phase 3 29, Phase 4 4, N/A 33.

Most active sponsors, by phase

SponsorActive trialsBy phaseNew (window)Upcoming readouts
Neurocrine Biosciences NBIX6P3 5, P4 100
Intra-Cellular Therapies, Inc.3P3 311
Janssen Research & Development, LLC3P3 301
Eli Lilly and Company LLY3P2 1, P3 220
Chengdu Kanghong Pharmaceutical Group Co., Ltd. new entrant2P3 220
Cybin IRL Limited2P3 200
Definium Therapeutics US, Inc. DFTX2P3 200
Xenon Pharmaceuticals Inc. XENE2P3 202
Axsome Therapeutics, Inc. AXSM2P4 1, P3 100
Bukwang Pharmaceutical new entrant1P3 110
CSPC Ouyi Pharmaceutical Co., Ltd.1P3 100
Senseye, Inc.1P3 100
Sunshine Lake Pharma Co., Ltd. SBFM1P3 100
Takeda TAK1P3 100
Tasly Pharmaceutical Group Co., Ltd1P3 101
Vanda Pharmaceuticals VNDA1P3 100
Alto Neuroscience ANRO2P2 201
Draig Therapeutics Ltd2P2 211
Emobot2NA 201
Ionclinics & Deionic SL2NA 211
Luye Pharma Group Ltd.2P1 1, P4 101
Motif Neurotech, Inc.2NA 210
Psyrin Inc.2NA 200
Seaport Therapeutics SPTX2P2 202
Sichuan Credit Pharmaceutical Co., Ltd. new entrant2NA 221

New-entrant sponsors: Chengdu Kanghong Pharmaceutical Group Co., Ltd., Bukwang Pharmaceutical, Sichuan Credit Pharmaceutical Co., Ltd..

Recently stopped trials

Upcoming trial readouts (next 90 days)

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-12 est.P2Alto Neuroscience ANRONCT05922878 Study of ALTO-300 in MDDMajor Depressive Disorderrecruiting325
2026-12-30 est.P3Janssen Research & Development, LLCNCT06559306 Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia SymptomsDepressive Disorder, Majorrecruiting752
2026-12-31 est.P1/P2Mapi Pharma Ltd.NCT07185815 Pharmacokinetics, Safety, Tolerability and Efficacy of a Subcutaneous Long-Acting Injection of Cariprazine (Cariprazine Depot) in Subjects Eligible for TreatmenSchizophrenia; Bipolar I Disorder; Major Depressive Disorderrecruiting24
2026-12-31 est.P2Supernus Pharmaceuticals, Inc. SUPNNCT07226661 Double-blind, Placebo-controlled Study in Adults With Major Depressive DisorderMajor Depressive Disorder (MDD)recruiting230
2026-12-31 est.P2/P3Tasly Pharmaceutical Group Co., LtdNCT07485595 A Study of the Effectiveness and Safety of JS1-1-01 Tablet in Patients With Moderate to Severe DepressionDepressionnot yet recruiting180
2027-01 est.P3Xenon Pharmaceuticals Inc. XENENCT06922110 An Open-Label Study of Azetukalner in Major Depressive DisorderMajor Depressive Disorderactive not recruiting460

Readouts in the last 180 days

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-11 est.P2Beckley Psytech LimitedNCT05660642 An Open-Label Study to Evaluate the Safety, Tolerability and Pharmacodynamics of BPL-003 in Patients With Treatment Resistant DepressionTreatment Resistant Depressionrecruiting72
2026-10-28P3Xenon Pharmaceuticals Inc. XENENCT06775379 A Randomized Study of Azetukalner Versus Placebo in Major Depressive DisorderMajor Depressive Disorderterminated357
2026-09-30 est.P3CSPC Ouyi Pharmaceutical Co., Ltd.NCT06958692 A Trial of Dextromethorphan and Bupropion Sustained-Release Tablets in Patients With Major Depressive DisorderMajor Depressive Disorder (MDD)recruiting388
2026-09-04P3Cybin IRL LimitedNCT06564818 "A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder"Major Depressive Disordercompleted223
2026-08-17P3Neumora Therapeutics, Inc. NMRANCT06029439 Study to Assess the Safety and Effectiveness of NMRA-335140-501Major Depressive Disorderterminated904
2026-07-30P2atai Therapeutics, Inc.NCT06524830 A Study to Assess the Efficacy, Safety and Tolerability of VLS-01 Buccal Film, Compared to Placebo in Patients With Treatment Resistant Depression (ELUMINA)Treatment Resistant Depressioncompleted142
2026-07-27P2AbbVie ABBVNCT06236880 A Phase 2a Study to Evaluate the Safety and Tolerability of GM-2505 in Patients With MDDMajor Depressive Disordercompleted126
2026-07-14P3CSPC ZhongQi Pharmaceutical Technology Co., Ltd.NCT06827431 The Research of Ammoxetine Hydrochloride Enteric-coated Tablets in Subjects With DepressionMajor Depressive Disorder (MDD)completed786
2026-07-08P2Sirtsei Pharmaceuticals, Inc.NCT06254612 A Study of the Efficacy and Safety of SP-624 in the Treatment of Adults With Major Depressive DisorderMajor Depressive Disordercompleted497
2026-06-25P2Hangzhou PhecdaMed Co., Ltd.NCT07018245 Clinical Trial of TJ0113 Capsules in the Treatment of Patients With Depressive DisorderDepressioncompleted149
2026-06-25P2Janssen Research & Development, LLCNCT06785012 A Study to Explore the Efficacy of JNJ-89495120 in the Treatment of Major Depressive DisorderDepressive Disorder, Majorcompleted105
2026-06 est.P2Autobahn Therapeutics, Inc.NCT06633016 Study of ABX-002 for the Adjunctive Treatment of Major Depressive Disorder (AMPLIFY)Major Depressive Disorderrecruiting230

Landscape counts: ClinicalTrials.gov, industry lead sponsors, active statuses, via the free hosted BioCatalystFeed MCP tool condition_landscape (query "major depressive disorder"); readouts matched by condition text. Registry counts only; not a forecast.

Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA (openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score. Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP readout_calendar / fda_decisions. Not investment advice.